Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

A method for separating particles in a biofluid includes pretreating the biofluid by introducing an additive, flowing the pretreated biofluid through a microfluidic separation channel, and applying acoustic energy to the microfluidic separation channel. A system for microfluidic separation, capable of separating target particles from non-target particles in a biofluid includes at least one microfluidic separation channel, a source of biofluid, a source of additive, and at least one acoustic transducer coupled to the microfluidic separation channel. A kit for microfluidic particle separation includes a microfluidic separation channel connected to an acoustic transducer, a source of an additive, and instructions for use.

The invention relates to a method to prevent contrast-induced nephropathy during an imaging procedure. The method includes the step of positioning balloon catheters in a patient's renal arteries and inflating the balloons of each catheter to block the flow of contrast media into the patient's kidneys.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.

Provided is a blood purifying apparatus having a fluid pumping device, which further includes first to sixth chambers each having an internal space, a chamber pressurizing member compressing or expanding the internal spaces of the fluid chambers, a chamber pressurizing member driver driving the chamber pressurizing member, and a flow controller. The chambers are each connected with a first flow tube through which a fluid is provided to the chamber and a second flow tube through which a fluid of the chamber is discharged therefrom. The flow controller controls a flow passage through the flow tubes connected to the first to fourth chambers.

Described are embodiments that include methods and devices for separating composite liquids into components. Embodiments involve the use of a flexible membrane for separating a composite liquid into components. The composite liquid may include, in embodiments, a cellular containing liquid, such as whole blood or components of whole blood. In one specific embodiment, the composite liquid is a buffy coat.

A device for the processing and separation of biological fluids into components comprises a hollow centrifugal processing chamber (10) fitted with an inlet/outlet head (20) and preferably with an axially movable piston (18). The inlet/outlet head has two separate inlets/outlets, for instance an axial inlet (29) and a lateral outlet (40). The processing chamber (1) is fitted with an internal flow guide (30) enabling operation of the device in a continuous processing mode wherein biological fluid to be processed is continuously intaken by say the axial inlet (29) and at the same time processed components are continuously removed via say the lateral outlet (40). The continuous processing flow can be driven by an external peristaltic pump (59) and/or by axial displacement of a piston (18) in the chamber (10).

A dialysis system is disclosed. The dialysis system includes a water purification unit, at least one pump in fluid communication with the water purification unit, a first concentrate source for creating peritoneal dialysis fluid, a second concentrate source for creating blood treatment dialysis fluid, a blood filter for receiving the blood treatment dialysis fluid, and a control unit. The control unit controls the at least one pump to perform a peritoneal dialysis treatment by delivering, to a patient, peritoneal dialysis fluid that is mixed from the water and concentrate from the first concentrate source. The control unit also controls the at least one pump to perform a blood treatment by delivering, to the blood filter, blood treatment dialysis fluid that is mixed from the water and concentrate from the second concentrate source.